Episode Details
Back to Episodes
Dare Bioscience: Revolutionizing Women's Health
Description
Dare Biosciences Q1 2026 earnings showcase a strong focus on womens health innovations, with $18.5 million in cash and a dual strategy of selling compounded drugs and pursuing FDA approvals. Key cash burn remained low, and theyre poised for first-ever product revenue this year. DARE to PLAY, a topical sildenafil cream for arousal, is now available in all 50 states, and DARE to RESTOREs probiotic hits shelves in June. Clinicians praise Dares data-driven formulations, and the company is filling gaps in womens health with a grant-funded pipeline. Ovaprenes phase three trial shows positive results, and DARE-HPV starts phase two this month. Dare is set to become a revenue machine in an underfunded space, with multiple wins and potential partnerships ahead.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/fcc45cd3dfb61b59